Prothena Corporation plc
Index- P/E21.80 EPS (ttm)1.23 Insider Own0.08% Shs Outstand46.70M Perf Week4.61%
Market Cap1.24B Forward P/E- EPS next Y-3.59 Insider Trans- Shs Float46.70M Perf Month0.64%
Income67.40M PEG- EPS next Q-0.52 Inst Own99.90% Short Float7.71% Perf Quarter-27.57%
Sales201.60M P/S6.16 EPS this Y149.60% Inst Trans3.13% Short Ratio8.34 Perf Half Y-43.56%
Book/sh9.40 P/B2.85 EPS next Y-26.70% ROA11.90% Target Price66.67 Perf Year-45.06%
Cash/sh11.70 P/C2.29 EPS next 5Y-0.60% ROE16.00% 52W Range21.06 - 79.75 Perf YTD-45.81%
Dividend- P/FCF14.06 EPS past 5Y18.10% ROI14.40% 52W High-66.43% Beta1.29
Dividend %- Quick Ratio15.20 Sales past 5Y185.60% Gross Margin- 52W Low27.11% ATR1.86
Employees82 Current Ratio15.20 Sales Q/Q500.00% Oper. Margin32.90% RSI (14)50.86 Volatility7.22% 7.47%
OptionableYes Debt/Eq0.00 EPS Q/Q14.90% Profit Margin33.40% Rel Volume0.51 Prev Close27.61
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout0.00% Avg Volume431.65K Price26.77
Recom1.70 SMA202.77% SMA50-4.11% SMA200-38.02% Volume219,867 Change-3.04%
Nov-19-21Initiated JMP Securities Mkt Outperform $77
Jun-18-21Upgrade BofA Securities Underperform → Neutral $12 → $49
Jun-08-21Reiterated Oppenheimer Outperform $45 → $54
May-26-21Initiated Citigroup Buy $39
Feb-26-21Upgrade RBC Capital Mkts Sector Perform → Outperform $14 → $28
Feb-12-21Upgrade Jefferies Hold → Buy $15 → $30
Feb-02-21Upgrade BTIG Research Neutral → Buy $29
Dec-07-20Initiated H.C. Wainwright Buy $22
Jul-09-20Upgrade Oppenheimer Perform → Outperform $16
Nov-19-19Upgrade Evercore ISI In-line → Outperform $14
May-21-18Downgrade Barclays Equal Weight → Underweight $14 → $12
Apr-23-18Downgrade Jefferies Buy → Hold
Apr-05-18Reiterated Barclays Overweight $70 → $50
Nov-20-17Downgrade Wedbush Outperform → Neutral $75 → $55
Sep-29-17Reiterated BTIG Research Buy $80 → $77
Sep-15-17Initiated RBC Capital Mkts Outperform $87
Aug-17-17Initiated Evercore ISI Outperform $83
Jul-11-17Initiated Jefferies Buy
Apr-12-17Initiated Piper Jaffray Overweight $69
Apr-12-17Initiated Cantor Fitzgerald Overweight $86
Jun-22-22 10:47AM  
Jun-09-22 11:30AM  
Jun-02-22 04:05PM  
May-08-22 08:02AM  
May-06-22 12:24PM  
May-05-22 06:35PM  
May-02-22 03:44PM  
Apr-28-22 04:05PM  
Apr-26-22 08:30AM  
Apr-21-22 10:13AM  
Mar-29-22 11:44AM  
Mar-28-22 08:30AM  
Mar-21-22 04:05PM  
Mar-16-22 09:20AM  
Feb-18-22 10:05AM  
Feb-17-22 05:45PM  
Feb-10-22 04:05PM  
Feb-03-22 05:38PM  
Jan-28-22 01:38PM  
Jan-27-22 01:38PM  
Jan-18-22 02:57PM  
Jan-10-22 11:02AM  
Dec-23-21 08:09AM  
Dec-12-21 03:55PM  
Dec-07-21 01:51PM  
Dec-03-21 11:58AM  
Nov-29-21 04:05PM  
Nov-25-21 08:25AM  
Nov-22-21 10:38AM  
Nov-18-21 08:43AM  
Nov-10-21 09:14AM  
Nov-05-21 08:59AM  
Nov-04-21 08:56PM  
Nov-01-21 11:26AM  
Oct-28-21 04:05PM  
Oct-27-21 03:03PM  
Oct-26-21 02:03PM  
Oct-23-21 06:08AM  
Oct-15-21 09:34AM  
Oct-12-21 11:40AM  
Oct-11-21 01:06PM  
Oct-04-21 11:54AM  
Oct-01-21 04:30PM  
Sep-23-21 11:40AM  
Sep-18-21 09:13AM  
Sep-09-21 12:00PM  
Sep-03-21 04:05PM  
Sep-01-21 04:05PM  
Aug-25-21 04:46AM  
Aug-11-21 08:02AM  
Aug-09-21 01:32AM  
Aug-06-21 12:41PM  
Aug-05-21 05:25PM  
Aug-03-21 11:33AM  
Jul-29-21 04:05PM  
Jul-26-21 03:27PM  
Jul-20-21 04:05PM  
Jul-17-21 07:37AM  
Jul-16-21 11:40AM  
Jul-14-21 03:21PM  
Jul-13-21 12:22PM  
Jul-12-21 12:45PM  
Jun-24-21 08:30AM  
Jun-18-21 04:53AM  
Jun-10-21 04:19PM  
Jun-09-21 04:58AM  
May-20-21 04:05PM  
May-12-21 03:32PM  
May-11-21 04:05PM  
May-10-21 04:05PM  
May-07-21 04:05PM  
May-04-21 04:05PM  
Apr-28-21 12:33PM  
Apr-18-21 03:05PM  
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EcoR1 Capital, LLC10% OwnerMay 05Buy29.021,062,73630,840,59911,584,280May 09 06:01 AM
EcoR1 Capital, LLC10% OwnerMay 05Sale29.021,062,73630,840,59911,584,280May 09 06:01 AM
Cooke ShaneDirectorApr 11Option Exercise6.415,00032,0505,000Apr 13 09:45 PM
Cooke ShaneDirectorApr 11Sale35.085,000175,3820Apr 13 09:45 PM
COLLIER RICHARD TDirectorApr 05Option Exercise6.415,00032,0506,219Apr 07 09:47 PM
COLLIER RICHARD TDirectorApr 05Sale39.415,000197,0271,219Apr 07 09:47 PM
EcoR1 Capital, LLC10% OwnerJan 12Buy37.50300,00011,250,30011,584,280Jan 12 06:12 PM
Selkoe Dennis J.DirectorJan 03Option Exercise9.235,00046,1507,845Jan 05 09:02 PM
Selkoe Dennis J.DirectorJan 03Sale47.455,000237,2332,845Jan 05 09:02 PM
Walker Karin LChief Accounting OfficerNov 23Option Exercise15.044,51967,9664,519Nov 26 09:19 PM
Walker Karin LChief Accounting OfficerNov 23Sale57.884,519261,5730Nov 26 09:19 PM
Malecek Michael JSee RemarksNov 19Option Exercise10.2710,000102,70010,000Nov 19 09:32 PM
Malecek Michael JSee RemarksNov 19Sale55.0010,000550,0000Nov 19 09:32 PM
Karp Carol D.Chief Regulatory OfficerNov 01Option Exercise15.0410,000150,40010,000Nov 03 09:17 PM
Karp Carol D.Chief Regulatory OfficerNov 01Sale57.1810,000571,8180Nov 03 09:17 PM
Malecek Michael JSee RemarksOct 27Option Exercise10.2710,000102,70010,000Oct 29 05:00 PM
Malecek Michael JSee RemarksOct 27Sale58.5210,000585,2500Oct 29 05:00 PM
Walker Karin LChief Accounting OfficerOct 20Option Exercise16.9723,000390,23023,000Oct 22 05:53 PM
Walker Karin LChief Accounting OfficerOct 20Sale60.2523,0001,385,8230Oct 22 05:53 PM
Karp Carol D.Chief Regulatory OfficerOct 01Option Exercise15.0410,000150,40010,000Oct 01 08:46 PM
Selkoe Dennis J.DirectorOct 01Option Exercise9.235,00046,1507,845Oct 01 09:18 PM
Karp Carol D.Chief Regulatory OfficerOct 01Sale68.2310,000682,3360Oct 01 08:46 PM
Selkoe Dennis J.DirectorOct 01Sale67.845,000339,1762,845Oct 01 09:18 PM
Karp Carol D.Chief Regulatory OfficerSep 09Option Exercise15.0410,000150,40010,000Sep 10 05:06 PM
Karp Carol D.Chief Regulatory OfficerSep 09Sale71.9810,000719,8470Sep 10 05:06 PM
Selkoe Dennis J.DirectorJul 30Option Exercise14.265,00071,3157,845Jul 30 08:04 PM
Selkoe Dennis J.DirectorJul 30Sale49.475,000247,3742,845Jul 30 08:04 PM
HENNEY CHRISTOPHER SDirectorJul 14Option Exercise11.3311,108125,85411,108Jul 16 04:02 PM
HENNEY CHRISTOPHER SDirectorJul 14Sale55.4611,108616,0200Jul 16 04:02 PM
HENNEY CHRISTOPHER SDirectorJul 12Option Exercise9.7923,892233,94617,500Jul 12 09:37 PM
HENNEY CHRISTOPHER SDirectorJul 12Sale55.5123,8921,326,1280Jul 12 09:37 PM